IL323616A - Bifunctional compounds for degradation of BRAF in the ubiquitin-proteasome pathway - Google Patents
Bifunctional compounds for degradation of BRAF in the ubiquitin-proteasome pathwayInfo
- Publication number
- IL323616A IL323616A IL323616A IL32361625A IL323616A IL 323616 A IL323616 A IL 323616A IL 323616 A IL323616 A IL 323616A IL 32361625 A IL32361625 A IL 32361625A IL 323616 A IL323616 A IL 323616A
- Authority
- IL
- Israel
- Prior art keywords
- fluorophenyl
- piperidin
- sulfonamide
- pyridin
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363462918P | 2023-04-28 | 2023-04-28 | |
| PCT/US2024/026679 WO2024227104A1 (fr) | 2023-04-28 | 2024-04-26 | Composés bifonctionnels pour dégrader le braf par l'intermédiaire d'une voie ubiquitine-protéosome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL323616A true IL323616A (en) | 2025-11-01 |
Family
ID=91376068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL323616A IL323616A (en) | 2023-04-28 | 2025-09-28 | Bifunctional compounds for degradation of BRAF in the ubiquitin-proteasome pathway |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4702014A1 (fr) |
| JP (1) | JP2026517764A (fr) |
| KR (1) | KR20260005915A (fr) |
| CN (1) | CN121548574A (fr) |
| AU (1) | AU2024260700A1 (fr) |
| IL (1) | IL323616A (fr) |
| MX (1) | MX2025012819A (fr) |
| WO (1) | WO2024227104A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3867242A1 (fr) | 2018-10-15 | 2021-08-25 | Nurix Therapeutics, Inc. | Composés bifonctionnels pour la dégradation de btk par l'intermédiaire d'une voie ubiquitine-protéasome |
| EP3924350A1 (fr) | 2019-02-13 | 2021-12-22 | Nurix Therapeutics, Inc. | Composés bifonctionnels pour la dégradation de btk par l'intermédiaire d'une voie ubiquitine-protéasome |
| CA3160713A1 (fr) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Composes bifonctionnels pour la degradation de la btk par l'intermediaire de la voie de l'ubiquitine-proteosome |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112812109B (zh) * | 2019-11-18 | 2022-06-21 | 中国科学院微生物研究所 | 化合物DaP-01及其制备方法和应用 |
| EP4232023A4 (fr) * | 2020-10-26 | 2025-11-12 | Dana Farber Cancer Inst Inc | Composés pour la dégradation ciblée de protéines de kinases |
| MX2023012981A (es) * | 2021-05-03 | 2024-01-11 | Nurix Therapeutics Inc | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. |
-
2024
- 2024-04-26 CN CN202480042362.9A patent/CN121548574A/zh active Pending
- 2024-04-26 WO PCT/US2024/026679 patent/WO2024227104A1/fr not_active Ceased
- 2024-04-26 EP EP24730823.2A patent/EP4702014A1/fr active Pending
- 2024-04-26 KR KR1020257037277A patent/KR20260005915A/ko active Pending
- 2024-04-26 JP JP2025563017A patent/JP2026517764A/ja active Pending
- 2024-04-26 AU AU2024260700A patent/AU2024260700A1/en active Pending
-
2025
- 2025-09-28 IL IL323616A patent/IL323616A/en unknown
- 2025-10-27 MX MX2025012819A patent/MX2025012819A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024260700A1 (en) | 2025-11-13 |
| EP4702014A1 (fr) | 2026-03-04 |
| KR20260005915A (ko) | 2026-01-12 |
| MX2025012819A (es) | 2025-12-01 |
| CN121548574A (zh) | 2026-02-17 |
| JP2026517764A (ja) | 2026-06-02 |
| WO2024227104A1 (fr) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7741282B2 (ja) | ユビキチンプロテオソーム経路を介してbtkを分解するための二官能性化合物 | |
| US12600732B2 (en) | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | |
| US20230158151A1 (en) | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use | |
| US20240279202A1 (en) | Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use | |
| KR20260005915A (ko) | 유비퀴틴-프로테아좀 경로를 통한 braf 분해용 이중기능 화합물 | |
| US20250002489A1 (en) | Bifunctional compounds for degrading itk via ubiquitin proteosome pathway | |
| WO2025111513A1 (fr) | Composés utiles dans la modulation de l'activité de klhdc1 et de klhdc2 | |
| BR122023025072A2 (pt) | Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma | |
| HK40081936A (en) | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |